Literature DB >> 20699437

Androgen deprivation induces rapid involution and recovery of human prostate vasculature.

Alejandro Godoy1, Viviana P Montecinos, Danny R Gray, Paula Sotomayor, Jeffrey M Yau, R Robert Vethanayagam, Swaroop Singh, James L Mohler, Gary J Smith.   

Abstract

The response of the prostate tissue microenvironment to androgen deprivation (AD) represents a critical component in the treatment of benign prostatic hyperplasia and prostate cancer (CaP). Primary xenografts of human benign and CaP tissue transplanted to immunocompromized SCID mice were used to characterize the response of the prostate vasculature during the initial 14 days of AD. Microvessel density and vascular lumen diameter in the prostate xenografts decreased rapidly after AD, reached a nadir on days 2-4, and recovered between days 4 and 14. The number of apoptotic endothelial cells peaked on day 2 after AD and decreased to precastration levels over days 4-7. Leakage of vascular contents in the interstitial space was apparent between days 1 and 3 after AD; however, the vascular permeability barrier reestablished between days 7 and 14. Expression of vascular endothelial growth factor (VEGF)-A, VEGF receptor-2, and basic fibroblast growth factor protein increased in endothelial cells between days 2 and 4 after AD, which preceded vascular recovery and appeared to be a direct and specific response of the endothelial cells to AD. Lack of comparable upregulation of these genes in primary cultures of human prostate endothelial cells in response to AD suggests a role for paracrine signaling mediated through stromal or epithelial cells. VEGF-A expression by prostate endothelial cells appears to represent a key facilitator of the vascular rebound in human prostate tissue induced by removal of circulating testicular androgens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20699437      PMCID: PMC3280699          DOI: 10.1152/ajpendo.00210.2010

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  66 in total

Review 1.  Angiogenesis as a strategic target for prostate cancer therapy.

Authors:  Yong Li; Paul J Cozzi
Journal:  Med Res Rev       Date:  2010-01       Impact factor: 12.944

Review 2.  Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.

Authors:  J E Oesterling; M F el Etreby; G J Gormley; J L Imperato-McGinley; C G Roehrborn; F H Schröder; U W Tunn
Journal:  Prog Clin Biol Res       Date:  1994

Review 3.  Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence.

Authors:  J Folkman
Journal:  Endocrinology       Date:  1998-02       Impact factor: 4.736

4.  Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.

Authors:  M J Wilson; A A Sinha
Journal:  Anat Rec       Date:  1997-09

5.  Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration.

Authors:  E Lekås; M Johansson; A Widmark; A Bergh; J E Damber
Journal:  Urol Res       Date:  1997

6.  Immunohistochemical demonstration of androgen receptors in human salivary glands.

Authors:  M Laine; M Bläuer; T Ylikomi; P Tuohimaa; K Aitasalo; R P Happonen; J Tenovuo
Journal:  Arch Oral Biol       Date:  1993-04       Impact factor: 2.633

Review 7.  Endocrine therapies for symptomatic benign prostatic hyperplasia.

Authors:  J E Oesterling
Journal:  Urology       Date:  1994-02       Impact factor: 2.649

Review 8.  Angiogenesis inhibition in the treatment of prostate cancer.

Authors:  Ravi A Madan; William L Dahut
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

Review 9.  Finasteride: a clinical review.

Authors:  G J Gormley
Journal:  Biomed Pharmacother       Date:  1995       Impact factor: 6.529

Review 10.  Hormone-refractory (D3) prostate cancer: refining the concept.

Authors:  H I Scher; G Steineck; W K Kelly
Journal:  Urology       Date:  1995-08       Impact factor: 2.649

View more
  25 in total

1.  Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration.

Authors:  Yue Wu; Li Tang; Gissou Azabdaftari; Elena Pop; Gary J Smith
Journal:  Mol Cell Endocrinol       Date:  2019-02-23       Impact factor: 4.102

Review 2.  Androgen receptor in human endothelial cells.

Authors:  Verónica Torres-Estay; Daniela V Carreño; Ignacio F San Francisco; Paula Sotomayor; Alejandro S Godoy; Gary J Smith
Journal:  J Endocrinol       Date:  2015-01-06       Impact factor: 4.286

3.  Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer.

Authors:  Kathrine Røe; Lars Tg Mikalsen; Albert J van der Kogel; Johan Bussink; Heidi Lyng; Anne H Ree; Laure Marignol; Dag R Olsen
Journal:  Radiat Oncol       Date:  2012-05-23       Impact factor: 3.481

4.  Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress.

Authors:  Joo Hyoung Lee; Minsung Kang; Hong Wang; Gurudatta Naik; James A Mobley; Guru Sonpavde; W Timothy Garvey; Victor M Darley-Usmar; Selvarangan Ponnazhagan
Journal:  FASEB J       Date:  2017-01-09       Impact factor: 5.191

Review 5.  Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance.

Authors:  Christine Levesque; Peter S Nelson
Journal:  Cold Spring Harb Perspect Med       Date:  2018-08-01       Impact factor: 6.915

Review 6.  Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate.

Authors:  Alejandro S Godoy; Ivy Chung; Viviana P Montecinos; Ralph Buttyan; Candace S Johnson; Gary J Smith
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-04-02       Impact factor: 4.310

7.  Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.

Authors:  Xiaohai Wang; Soo Ok Lee; Shujie Xia; Qi Jiang; Jie Luo; Lei Li; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

8.  Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).

Authors:  Kuo-Pao Lai; Chiung-Kuei Huang; Lei-Ya Fang; Kouji Izumi; Chi-Wen Lo; Ronald Wood; Jon Kindblom; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Endocrinol       Date:  2013-07-26

9.  Fibroblasts prolong serum prostate-specific antigen decline after androgen deprivation therapy in prostate cancer.

Authors:  Takeshi Sasaki; Kenichiro Ishii; Yoichi Iwamoto; Manabu Kato; Manabu Miki; Hideki Kanda; Kiminobu Arima; Taizo Shiraishi; Yoshiki Sugimura
Journal:  Lab Invest       Date:  2015-12-07       Impact factor: 5.662

Review 10.  The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.

Authors:  Michael V Fiandalo; Wenjie Wu; James L Mohler
Journal:  Curr Drug Targets       Date:  2013-04       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.